JANX Q4 2023 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$852M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-13.5% YoY

Gross Profit

$2M78.4% margin

Operating Income

-$16M-655.7% margin

Net Income

-$12M-477.8% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

-2.2%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$380M

Total Liabilities

$36M

Stockholders' Equity

$344M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$3M	-13.5%
Gross Profit	$2M	$3M	-32.2%
Operating Income	-$16M	-$18M	+11.7%
Net Income	-$12M	-$16M	+26.8%